Wallonia Nordics’ Post

🔬 Metaphore Biotechnologies Launches with $50M to Transform Drug Development Through Biomimicry TL;DR: • Flagship Pioneering startup leveraging nature's molecular blueprints • Novel platform mimics biological interactions for therapeutic development • Focus on autoimmune, metabolic, and cancer treatments • Led by industry veterans Lovisa Afzelius (CEO) and Daniel Acker (CIO) Metaphore's innovative approach draws inspiration from nature's own solutions - much like the owl butterfly's evolved defense mechanisms. Their platform isolates and replicates pharmacophores (key molecular features), enhanced by machine learning to accelerate drug discovery. Based in Cambridge, MA, the company uniquely positions itself at the intersection of computational and experimental science, enabling seamless development of multiple therapeutic modalities. While the biotech sector faces challenges, with some platform companies under increased investor scrutiny, Metaphore's strong backing and versatile technology platform signal promising potential for breakthrough therapeutics. 💭 What are your thoughts on biomimicry in drug development? Share your insights on this innovative approach. #Biotech #DrugDiscovery #Innovation #Biomimicry #BiotechNews #intelligencesimplified #pharma #biotech #biodatastudio

🔬 Nuclera Awarded £1.1m Innovate UK Funding! 🎉 Nuclera, a cutting-edge biotechnology company, has secured over £1.1 million from Innovate UK to revolutionize protein expression and purification with their benchtop eProtein Discovery system. 🌟 💡 Key Funding Highlights: £790k FASST Grant: Awarded in collaboration with DeepMirror, under the Innovate UK Transforming Medicines Manufacturing (TMM) program, to develop innovative technologies for faster patient access to new drugs and treatments. 💊 £350k Engineering Biology Grant: To advance the platform with evaluations by experts Dr. Konstantinos Beis from Imperial College London and Dr. Andrew Quigley from Diamond Light Source. This grant is part of the UKRI Technology Missions Fund, aiming to address health, environment, and sustainability challenges. 🌍 🔍 Innovative Collaboration: Nuclera is accelerating drug discovery processes by up to 30x with the eProtein Discovery platform, offering rapid access to challenging proteins in less than 48 hours. ⏱️ The platform overcomes traditional manufacturing challenges, providing sequences and optimal conditions for protein manufacturing. ⚙️ Collaboration with DeepMirror, Dr. Beis, and Dr. Quigley will ensure the success and advancement of these groundbreaking projects. 🤝 🗣️ Expert Opinions: Dr. Michael Chen, CEO and co-founder of Nuclera, highlights the power of eProtein Discovery in addressing global challenges in manufacturing and engineering biology. 🌐 Dr. Andrew Quigley from Diamond’s Membrane Protein Lab (MPL) emphasizes the platform's potential in assessing conditions for functional protein, supported by MPL's extensive resources. 🔬 Nuclera’s innovative efforts are paving the way for faster and more efficient drug discovery, driving significant advancements in biotechnology. 🚀 🔗 Full Article: https://lnkd.in/ed9ZpAcp Stay tuned for more updates on how Nuclera is transforming the biotech landscape! 🌟 #Biotechnology #InnovateUK #Funding #eProteinDiscovery #DrugDiscovery #Innovation

Nobel laureate David Baker launched Archon Biosciences out of stealth to introduce a new class of biologics. Driven by AI-guided protein design, Archon has developed Antibody Cages (AbCs)—precisely engineered structures aimed at treating diseases that conventional therapies have struggled to address. With $20 million in seed funding led by Madrona Venture Labs, alongside DUMAC and Washington Research Foundation, Archon is prepared to advance its AI-based antibody structures into the therapeutic realm. James Lazarovits (CEO of Archon) describes AbCs as a way to enable greater control over therapeutic delivery and engagement with disease targets, potentially broadening treatment options for complex conditions. Archon’s approach exemplifies how AI is enabling significant progress in biologics, reinforcing its role in the future of drug discovery. George Ueda Craig Halder University of Washington Alexandria Real Estate Equities, Inc. Sahsen Ventures, LLC Pack Ventures Cornucopian Capital #Biopharma #Biotech #AIinBiotech #DrugDiscovery #ProteinDesign #Innovation #AIinHealthcare #BiotechInnovation

Excited to have led the closing panel entitled "Bridging Science and Investment" in San Diego, CA. Joined by Dr. Sanjeev Thohan (Cogentis Therapeutics, Inc./Phoenix Molecular Designs) and Dr. Yuhua Ji (Grace Science, LLC ), we explored the intersection of scientific innovation and investment strategies. Key topics of this thought-provoking panel included: - Strategic investment approaches in the evolving biotech landscape - The critical role of venture capital in accelerating drug discovery - Innovative funding models for cutting-edge pharmaceutical research - The future of biotechnologies and the investment opportunities they present Thank you to the panelists for sharing their invaluable insights. Our discussion underscored the vital role of strategic investments in driving innovation and shaping the future of drug discovery and development. Together, we are paving the way for groundbreaking advancements in biotech. #biotechnology #MedicinalChemistry, #strategy #drugdevelopment Proventa International #Bio2024 BIO International Convention #DrugDiscovery #Investment #VentureCapital #Biotech #SanDiego American Association for Precision Medicine (AAPM) WISE World Investors & Entrepreneurs Society Agility Pharmaceuticals Precision BioPharma #ai #news

Everyone is talking about the German biotech financing gap, but are you aware of the many success stories written by the sector?   German biotech companies not only grew significantly across key industry metrics but also capture the global spotlight with their innovative power: ·        Strong growth in number of employees and R&D expenses ·        Revenues and market capitalization pointing upward over the long term ·        Biotech drug developers expanding their therapeutic pipelines ·        Alliances "biobucks" on high level (€11.4 billion) ·        Large-volume M&A deals in the first quarter of 2024 (€5.0 billion)   Furthermore, I am deeply impressed by Germany's biotech innovators who are leading the charge with breakthroughs in: ·        Next-generation radiopharmaceuticals ·        Microbiome-based therapeutics ·        Cutting-edge gene and cell therapies ·        Smart biotech materials ·        Revolutionary novel foods ·        And last but certainly not least, AI-powered solutions throughout various biotech application areas Dive into our German Biotechnology Report 2024 for an in-depth look at these success stories and more – of course we also analyze the German biotech financing gap: https://lnkd.in/egnQsNa4   What are the biotech achievements that inspire you the most? Share them in the comments!        #EYBiotech #BioDeutschland #Biotechnologie

👀 Excited about the future of biotechnology? Argenx is leading the way with strategic investor engagement at upcoming conferences! But what does this mean for future innovations and investments? 🌟 From autoimmune breakthroughs to global market expansions, dive into what makes their strategies a potential game-changer in biotech.✨ Stay ahead, understand the implications, and position yourself for success with the insights every investor and industry pro should know about. Are you ready to harness the momentum? 🌍🔍 #Biotech #Innovation #InvestmentOpportunities #argenx

𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝘂𝗻𝗱𝗲𝗿𝘀𝗰𝗼𝗿𝗲𝘀 𝗕𝗮𝘆𝗲𝗿´𝘀 𝗰𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝗰𝗿𝗲𝗮𝘁𝗶𝗻𝗴 𝗮 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 𝗳𝗼𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗕𝗲𝗿𝗹𝗶𝗻: Bayer announced the inauguration of its new life science incubator Bayer Co.Lab Berlin, located on the Global Headquarters Campus of Bayer’s Pharmaceuticals Division, near world-renowned research and clinical institutions. MyoPax GmbH, a Berlin-based start-up company specializing in muscle regeneration therapies and a spin-off from the Charité Universitaetsmedizin and the Max-Delbrueck-Center of the Helmholtz Association, will move into the new facility as the first resident. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eBsqtqaA Bayer, Christian Rommel, Verena Schöwel, Stefan Oelrich, Ruth R. Shah, Friedemann Janus, PhD, MyoPax, Juergen Eckhardt, Bayer Co.Lab

UQ's UniQuest partners with global biotech company Read more: 👇👇 https://buff.ly/3VEXz8T The University of Queensland #laboratory #science #lab #research #scientist #laboratorio #biotechnology #medical #laboratorylife #microbiologia #biotech #dna #microscopy #lablife #bhfyp #Labs_Online

🌟 Exciting News! 🌟 We’re thrilled to announce that our project, "Development and Implementation of a New Method for Direct Detection and Measurement of Replication Stress in Human Cells and Tissues," has received funding from the European Funds for Smart Economy (FENG) under the Ścieżka SMART program. Through advanced laboratory experiments using state-of-the-art equipment co-financed by this project, we aim to revolutionize the detection and measurement of replication stress in eukaryotic cells. Our innovative method will offer unparalleled sensitivity and specificity, going beyond current standards. Building on our STRIDE technology for identifying DNA breaks, we’re taking a step further: enabling the detection of active replication stress sites directly within cells. This process will be simple, fast, and non-invasive, making it suitable for both preclinical and clinical applications. The insights gained through this project will deepen our understanding of replication stress mechanisms, potentially leading to the discovery of new therapeutic targets. Additionally, our method will enhance drug assessment—especially for oncological treatments like DDR inhibitors—providing valuable tools for biotechnology and pharmaceutical companies, as well as research institutions. Stay tuned as we make strides in this exciting field. Follow our journey and keep your fingers crossed for our success! 🙌 #Innovation #Biotechnology #PharmaceuticalResearch #ReplicationStress #OncologyResearch #DrugDevelopment #LaboratoryScience #ClinicalResearch #EUFunding #DNAResearch #ScienceForHealth #STRIDE #FunduszeEuropejskie

🦤 This week, we have some big brain thinking in biotech (don’t we always?!) 2seventy bio’s plan to breakeven, Eli Lilly investing in a new drug manufacturing hub, cracking the code for off-the-shelf CAR-T therapy, and a neural map of the small fry fruit fly. Plus, let’s give a standing ovation to the Nobel Prize winners  – a very exciting result for biotech innovators!  👏 🇨🇳 World-first therapy using donor cells sends autoimmune diseases into remission (Smriti Felicitas Mallapaty) 🧫 As 2seventy nears breakeven, CEO Chip Baird explains how the team survived (Annalee Armstrong) 🏗️ Lilly shells out $4.5 billion for new drug development plant (Madison Muller) 🧠 Why a map of a fruit fly’s brain has neuroscientists ‘blown away’ (Anil Oza) 🏆 The Nobel Prizes 2024 (The Nobel Prize) Tune into… 🎧 What are vaccines? With Eliot Forster and Antonin de Fougerolles, former CEO of Evox Therapeutics 🎧 Automating bioprocessing to speed up workflows with Martin Tromp Permin, Co-Founder of Invert 🎧 From microbiome to macrobiome with Braden Tierney, Co-Founder and Executive Director of the The Two Frontiers Project Apply to… 📎 Supply Chain Engineer, Cellular Origins 📎 VP of Commercial Implementation, Culmination Bio 📎 VP, Next Generation Therapeutics, Asklepios BioPharmaceutical, Inc. (AskBio) Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #17 out now: https://lnkd.in/exJX9JrB #biotechdodo #biotech #pharma #digitalhealth #healthtech